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The author would like to make the below changes in the original article which was incorrectly published.

Page 751, Abstract, Results, line 2 which previously read:

Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, *P* = 0.04).

Should read:

Although median tumor size was similar between groups, the median tumor number was significantly higher in the S-TACE versus TACE-alone group (7 vs. 4, *P* \< 0.01).

Page 751, Abstract, Results, line 9 which previously read:

Median PFS (189 vs. 106 days, *P* = 0.02) and median overall survival time (861 vs. 467 days, *P* = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.

Should read:

Median PFS (189 vs. 106 days, *P* \< 0.01) and median overall survival time (861 vs. 467 days, *P* \< 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.

Page 752, Section 1, 1st column, line 46, the references which previously read:

"\[18\]"

Should read:

"\[19\]"

Page 753, Section 2.1, 2nd paragraph, line 1 which previously read:

Of the 95 patients, 24 patients who were previously non-responsive responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).

Should read:

Of the 95 patients, 24 patients who were previously non-responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).

Page 754, Section 3, 2nd column, line 10 which previously read:

The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (2 \[1--3\] vs. 1 \[0--2\], *P* \< 0.01) and radiofrequency ablation (4 \[1--5\] vs. 1 \[0--3\], *P* \< 0.01).

Should read:

The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (3 \[range 2--4\] vs. 2 \[range 2--3\], *P* \< 0.01) and radiofrequency ablation (4 \[range 1--5\] vs. 1 \[range 0--3\], *P* \< 0.01).

Page 755, Table 1, column 2, last row which previously read:

2 (1--3)

Should read:

3 (2--4)

Page 755, Table 1, column 3, last row which previously read:

1 (0--2)

Should read:

2 (2--3)

Page 756, Section 4, 2nd column, line 2, the references which previously read:

"\[22, 50, 51\]."

Should read:

"\[24, 50, 51\]."

Page 756, Section 4, 2nd column, line 13, the reference which previously read:

"\[52\]."

Should read:

"\[51\]."

Page 756, section 4, 2nd column, line 16, the reference which previously read:

"\[31\]"

Should read:

"\[32\]"

Page 756, Section 4, 2nd column, line 18, the references which previously read:

"\[32, 33, 52, 53\]."

Should read:

"\[32, 33, 51, 52\]."

Page 756, Section 4, 2nd column, line 26, the reference which previously read:

"\[54\]."

Should read:

"\[53\]."

Page 758, References: There were errors in the reference list. The corrected reference list is re-published below:
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